GlassScriptPhysician profile
Derek D Mcdonough
NPI 1245910686
$1,274.37
in general payments reported to CMS, 2019-2025
21 companies · $892 in 2025
The $892 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $383 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $380.94 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $286.75 | 2024-2025 | Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $89.93 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $86.91 | 2024-2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $51.27 | 2024-2025 | Zoryve |
| Vertex Pharmaceuticals Incorporated | $43.72 | 2025 | |
| Axsome Therapeutics, INC. | $39.84 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $37.44 | 2025 | Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $31.68 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.68 | 2025 | Jardiance |
| Viatris Specialty LLC | $23.69 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $21.41 | 2024 | Dupixent |
| Mylan Specialty L.P. | $20.78 | 2024 | Yupelri |
| Verona Pharma, INC. | $19.82 | 2025 | Ohtuvayre |
| Qiagen, LLC | $19.68 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16.75 | 2025 | Minimed 780g |
| Pfizer INC. | $16.37 | 2024 | |
| Dynavax Technologies Corporation | $16.13 | 2024 | Heplisav-B |
| Janssen Biotech, INC. | $16.00 | 2025 | Stelara, Tremfya, Simponi Aria |
| Exact Sciences Corporation | $14.15 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $13.43 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Mcdonough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.